Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 02, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial performance data.
Material Changes
On March 31, 2008, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary Shares and American Depository Shares (ADSs) under share allocation arrangements for the service period of January 1, 2008, to March 31, 2008. The specific allocations are as follows:
- Sir Christopher Gent: 2,694.47 ADSs
- Prof Sir Roy Anderson: 761.48 ADSs
- Dr Stephanie Burns: 321.03 ADSs
- Mr Lawrence Culp: 642.07 ADSs
- Sir Crispin Davis: 2,343.02 ADSs
- Sir Deryck Maughan: 642.07 ADSs
- Dr Daniel Podolsky: 481.55 ADSs
- Sir Ian Prosser: 1,522.96 ADSs
- Dr Ronaldo Schmitz: 937.21 ADSs
- Mr Tom de Swaan: 761.48 ADSs
- Sir Robert Wilson: 702.91 ADSs
The Company and the Non-Executive Directors were informed of these allocations on April 1, 2008.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the final vesting status of the provisional share allocations listed for Non-Executive Directors.
- Confirm the total number of ADSs and Ordinary Shares held by each director following this allocation.
- Review the specific terms of the share allocation arrangements for the period of January 1, 2008, to March 31, 2008.